The biotechnology sector is in a "bubble", pushing prices for medium-sized companies with experimental drugs in late-stage development out of reach, the chief executive of drugmaker Roche ( "I think this bubble will burst at some point," Severin Schwan told Reuters in an interview during a visit to London. The Swiss company continues to screen for promising acquisitions but the price of potential targets was now "far, far away" from fundamental value, he said.